# EDGAR Filing Document

**Accession Number:** 0001607678
**File Stem:** 0001193125-26-239535
**Filing Date:** 2026-5
**Character Count:** 7199
**Document Hash:** b17ca3879fa6b811d762c21aaa5bf251
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-239535.hdr.sgml**: 20260526

**ACCESSION NUMBER**: 0001193125-26-239535

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260519

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260526

**DATE AS OF CHANGE**: 20260526

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Viking Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001607678
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461073877
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37355
- **FILM NUMBER:** 261020718

**BUSINESS ADDRESS:**
- **STREET 1:** 9920 PACIFIC HEIGHTS BLVD, SUITE 350
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-704-4660

**MAIL ADDRESS:**
- **STREET 1:** 9920 PACIFIC HEIGHTS BLVD, SUITE 350
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 19, 2026<br>

------

Viking Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-37355 | 46-1073877 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 9920 Pacific Heights Blvd, Suite 500 |  |  |
| San Diego**,** California |  | 92121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 858 704-4660<br>

---

| |
|:---|
| Viking Therapeutics, Inc. |
| 9920 Pacific Heights Blvd, Suite 350 |
| San Diego**,** California 92121 |

---

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.00001 per share | VKTX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

------

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 19, 2026, Viking Therapeutics, Inc. (the "**Company**") held its 2026 Annual Meeting of Stockholders (the "**Annual Meeting**"). Of the 115,893,943 shares of the Company's common stock outstanding as of March 20, 2026, the record date for the Annual Meeting, 80,089,532 shares were represented at the Annual Meeting virtually or by proxy, constituting approximately 69.1% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business.

At the Annual Meeting, the Company's stockholders considered three proposals, each of which is described in more detail in the Company's revised definitive proxy statement filed with the Securities and Exchange Commission on April 1, 2026 (the "**Proxy Statement**").

Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

**Proposal No. 1.** To elect the following nominees as Class II directors to serve until the Company's 2029 annual meeting of stockholders or until such director's respective successor is duly elected and qualified:

---

| | | | |
|:---|:---|:---|:---|
| **Director Nominee** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| &nbsp;&nbsp;&nbsp;&nbsp;J. Matthew Singleton | 28,648,459 | 14,562,012 | 36,879,061 |
| &nbsp;&nbsp;&nbsp;&nbsp;S. Kathryn Rouan, Ph.D. | 21,960,203 | 21,250,268 | 36,879,061 |

---

As a result, the Company's stockholders voted to elect J. Matthew Singleton and S. Kathryn Rouan, Ph.D., as Class II directors to serve until the Company's 2029 annual meeting of stockholders or until such director's respective successor is duly elected and qualified.

**Proposal No. 2.** To ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| &nbsp;&nbsp;&nbsp;&nbsp;78,368,957 | 1,241,969 | 478,606 |

---

As a result, the Company's stockholders voted to ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026.

**Proposal No. 3.** To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| &nbsp;&nbsp;&nbsp;&nbsp;30,045,938 | 12,763,135 | 401,396 | 36,879,063 |

---

As a result, the Company's stockholders voted to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit No** | &nbsp;&nbsp;**Description** |
| &nbsp;&nbsp;104 | &nbsp;&nbsp;Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **VIKING THERAPEUTICS, INC.** |
| Date: | May 26, 2026 | By:  | /s/ Brian Lian, Ph.D. |
|  |  |  | Brian Lian, Ph.D.<br>President and Chief Executive Officer<br>(Principal Executive Officer) |

---

------